Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 447.51 Million CNY | 0.76% |
| 2022 | 444.14 Million CNY | 18.72% |
| 2021 | 374.1 Million CNY | -34.87% |
| 2020 | 574.36 Million CNY | -10.68% |
| 2019 | 643.03 Million CNY | 28.04% |
| 2018 | 502.21 Million CNY | 18.16% |
| 2017 | 425.03 Million CNY | 9.77% |
| 2016 | 387.2 Million CNY | 9.76% |
| 2015 | 352.76 Million CNY | 27.47% |
| 2014 | 276.73 Million CNY | 10.18% |
| 2013 | 251.16 Million CNY | 28.47% |
| 2012 | 195.49 Million CNY | 18.6% |
| 2011 | 164.84 Million CNY | 1231.51% |
| 2010 | 12.38 Million CNY | 1167.14% |
| 2009 | 977 Thousand CNY | -88.94% |
| 2008 | 8.83 Million CNY | -20.11% |
| 2007 | 11.05 Million CNY | -11.43% |
| 2006 | 12.48 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 108.52 Million CNY | 22.59% |
| 2024 Q2 | 86.84 Million CNY | -19.98% |
| 2023 Q2 | 104.51 Million CNY | -25.77% |
| 2023 FY | 447.51 Million CNY | 0.76% |
| 2023 Q3 | 113.66 Million CNY | 8.76% |
| 2023 Q1 | 140.8 Million CNY | 0.87% |
| 2023 Q4 | 88.52 Million CNY | -22.12% |
| 2022 FY | 444.14 Million CNY | 18.72% |
| 2022 Q4 | 139.58 Million CNY | 19.61% |
| 2022 Q1 | 97.54 Million CNY | -1.21% |
| 2022 Q2 | 90.31 Million CNY | -7.41% |
| 2022 Q3 | 116.7 Million CNY | 29.22% |
| 2021 Q1 | 118.14 Million CNY | -27.07% |
| 2021 Q4 | 98.73 Million CNY | 9.64% |
| 2021 Q3 | 90.06 Million CNY | 34.11% |
| 2021 FY | 374.1 Million CNY | -34.87% |
| 2021 Q2 | 67.15 Million CNY | -43.16% |
| 2020 Q4 | 161.99 Million CNY | -6.13% |
| 2020 FY | 574.36 Million CNY | -10.68% |
| 2020 Q1 | 91.85 Million CNY | -47.57% |
| 2020 Q2 | 147.94 Million CNY | 61.07% |
| 2020 Q3 | 172.56 Million CNY | 16.64% |
| 2019 Q3 | 177.33 Million CNY | 7.56% |
| 2019 Q2 | 164.87 Million CNY | 31.21% |
| 2019 FY | 643.03 Million CNY | 28.04% |
| 2019 Q1 | 125.65 Million CNY | -8.31% |
| 2019 Q4 | 175.17 Million CNY | -1.22% |
| 2018 Q1 | 115.33 Million CNY | -20.96% |
| 2018 FY | 502.21 Million CNY | 18.16% |
| 2018 Q4 | 137.04 Million CNY | 0.73% |
| 2018 Q3 | 136.05 Million CNY | 18.46% |
| 2018 Q2 | 114.85 Million CNY | -0.42% |
| 2017 FY | 425.03 Million CNY | 9.77% |
| 2017 Q3 | 105.83 Million CNY | 10.86% |
| 2017 Q2 | 95.46 Million CNY | 22.69% |
| 2017 Q1 | 77.81 Million CNY | -40.44% |
| 2017 Q4 | 145.91 Million CNY | 37.87% |
| 2016 Q1 | 70.15 Million CNY | -42.13% |
| 2016 Q2 | 96.63 Million CNY | 37.75% |
| 2016 Q3 | 89.77 Million CNY | -7.09% |
| 2016 FY | 387.2 Million CNY | 9.76% |
| 2016 Q4 | 130.64 Million CNY | 45.53% |
| 2015 Q1 | 67.15 Million CNY | -11.11% |
| 2015 Q2 | 81.87 Million CNY | 21.93% |
| 2015 FY | 352.76 Million CNY | 27.47% |
| 2015 Q4 | 121.22 Million CNY | 46.94% |
| 2015 Q3 | 82.5 Million CNY | 0.76% |
| 2014 FY | 276.73 Million CNY | 10.18% |
| 2014 Q2 | 73.32 Million CNY | 11.32% |
| 2014 Q4 | 75.54 Million CNY | 21.86% |
| 2014 Q3 | 61.99 Million CNY | -15.44% |
| 2014 Q1 | 65.86 Million CNY | 0.25% |
| 2013 FY | 251.16 Million CNY | 28.47% |
| 2013 Q4 | 65.7 Million CNY | 8.04% |
| 2013 Q1 | 69.23 Million CNY | 53.03% |
| 2013 Q3 | 60.81 Million CNY | 9.75% |
| 2013 Q2 | 55.41 Million CNY | -19.97% |
| 2012 Q2 | 56.13 Million CNY | 8.46% |
| 2012 Q4 | 45.24 Million CNY | 6.78% |
| 2012 Q3 | 42.37 Million CNY | -24.51% |
| 2012 Q1 | 51.75 Million CNY | 33.03% |
| 2012 FY | 195.49 Million CNY | 18.6% |
| 2011 Q3 | 42.38 Million CNY | 5.65% |
| 2011 FY | 164.84 Million CNY | 1231.51% |
| 2011 Q1 | 43.42 Million CNY | 258.88% |
| 2011 Q2 | 40.12 Million CNY | -7.61% |
| 2011 Q4 | 38.9 Million CNY | -8.23% |
| 2010 Q1 | 154 Thousand CNY | 252.48% |
| 2010 FY | 12.38 Million CNY | 1167.14% |
| 2010 Q4 | 12.1 Million CNY | 24102.0% |
| 2010 Q3 | 50 Thousand CNY | -33.33% |
| 2010 Q2 | 75 Thousand CNY | -51.3% |
| 2009 Q2 | -70 Thousand CNY | 0.0% |
| 2009 Q3 | 76 Thousand CNY | 208.57% |
| 2009 FY | 977 Thousand CNY | -88.94% |
| 2009 Q4 | -101 Thousand CNY | -232.89% |
| 2008 FY | 8.83 Million CNY | -20.11% |
| 2007 FY | 11.05 Million CNY | -11.43% |
| 2006 FY | 12.48 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -167.273% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 93.141% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -1454.991% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -13.348% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 1356.947% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 18.828% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 70.927% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 5.046% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -106.579% |
| SSY Group Limited | 3.48 Billion HKD | 87.174% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -40.103% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 27.876% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 98.968% |